⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 3, 2024Open Access

Supplementary Material S1 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy

Toshiaki Iwase Evan N. Cohen Hui Gao Angela Alexander Megumi Kai Vivian Chiv Xiaoping Wang Savitri Krishnamurthy Diane D. Liu Yu Shen Kumiko Kida Alexandre Reuben Rachel M. Layman David L. Ramírez Debasish Tripathy Stacy L. Moulder Clinton Yam Vicente Valero Bora Lim James M. Reuben Naoto T. Ueno

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Study Full Protocol

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Iwase et al. (2024) studied this question.

synapsesocial.com/papers/68e6672fb6db6435875f3a88 https://doi.org/10.1158/1078-0432.25956620

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Material S1 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy2024
2Supplementary Figure S3 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy2024
3Supplementary Figure S3 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy2024
4Supplementary Figure S2 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy2024
5Supplementary Figure S2 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy2024

More related papers

Supplementary Figure S4 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy2024
Supplementary Figure S4 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy2024
Supplementary Figure S6 from Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy2024